Update on the Pathogenesis and Therapy of Atopic Dermatitis
The DOI matches its Crossref record; 141 of the 141 references it cites were found in a registry or an index.
Abstract
Atopic dermatitis (AD) is a common inflammatory skin disorder characterized by recurrent eczematous lesions and intense itch. Although it most often starts in infancy and affects children, it is also highly prevalent in adults. In this article, the main aspects of AD have been updated, with a focus on the pathogenetic and therapeutic aspects. The pathogenesis of AD is complex, and it is evident that a strong genetic predisposition, epidermal dysfunction, skin microbiome abnormalities, immune dysregulation, and the neuroimmune system are critical in AD development. Mutations in the genes associated with disrupted epidermal barrier, exaggerated pathological inflammation and inadequate antimicrobial peptides can promote enhanced Th2 inflammation and mediate pruritus. Current understanding of etiology highlights gut microbial diversity, NK cell deficiency, and different immunological phenotype with age and race. For topical anti-inflammatory treatment for mild-to-severe AD, phosphodiesterase 4 inhibitors (PDE-4), JAK inhibitors, and microbiome transplantation with Roseomonas mucosa provided more management selections. The treatment of moderate-to-severe AD has been limited to merely symptomatic and relatively nonspecific immunosuppressive approaches. In-depth understanding of the pathogenesis of AD has led to the development of innovative and targeted therapies, such as biologic agents targeting interleukin (IL)-4, IL-13 and JAK/STAT inhibitors. Other potential therapeutic agents…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Distinct cytokine axes, including Th2-associated cytokines (IL-4, IL-13), the IL-17, IL-23 axis, and cytotoxic IFN-γ-mediated pathways, form the core of major inflammatory skin diseases discussed in this review.”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [6]
In the citing paper
“In parallel, neuroimmune mechanisms have emerged as important modulators of cytokine signaling, linking neuronal pathways to immune activation and contributing to disease symptoms such as pruritus [2,6].”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [6]
In the citing paper
“The IL-4/IL-13 axis signals through JAK-dependent pathways with downstream activation of STAT6, which is central to type 2 inflammation”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [6]
In the citing paper
“while IL-17 and IL-23 drive keratinocyte activation and chronic inflammation in psoriasis.”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [6]
In the citing paper
“These morphological and molecular features directly underpin the development of targeted drugs such as dupilumab, tralokinumab, and lebrikizumab.”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [6]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Williams, H. C., Leung, D. Y. M., Thestrup‐Pedersen, K., & David, T. J. (2000) · Cited by 4,599
Palmer, C. N. A., Irvine, A. D., Terron-Kwiatkowski, A., Zhao, Y., Liao, H., Lee, S. P., Goudie, D. R., Sandilands, A., Campbell, L. E., Smith, F. J. D., et al. (2006) · Nature Genetics · doi:10.1038/ng1767 · Cited by 2,978
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110 · cited 1×
“A total of 65% of patients in the dupilumab combined with TCS group achieved an EASI 75 compared with 22% treated with TCS only [95].”
ResultLangan, S. M., Irvine, A. D., & Weidinger, S. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31286-1 · Cited by 1,852
Filaggrin Mutations Associated with Skin and Allergic Diseases
Irvine, A. D., McLean, W. H. I., & Leung, D. Y. M. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011040 · Cited by 1,217 · cited 1×
“The FLG variants R501X and 2282del4 were found in approximately 10% of Northern Europeans [15], while FLG variants of P478S and 3321delA were found mainly in Asian AD populations, and rarely in European populations [16].”
BackgroundWollenberg, A., Barbarot, S., Bieber, T., Christen‐Zaech, S., Deleuran, M., Fink‐Wagner, A., Gieler, U., Girolomoni, G., Lau, S., Muraro, A., et al. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14891 · Cited by 1,181 · cited 3×
“Oral food challenge of AD patients may induce early reactions such as urticaria, gastrointestinal or respiratory symptoms usually occurring within 2 h after allergen administration (IgE-mediated), or eczematous late-phase responses after 18–48 h (none IgE-mediated) [61].”
BackgroundInfluentialTight junction defects in patients with atopic dermatitis
De Benedetto, A., Rafaels, N. M., McGirt, L. Y., Ivanov, A. I., Georas, S. N., Cheadle, C., Berger, A. E., Zhang, K., Vidyasagar, S., Yoshida, T., et al. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.10.018 · Cited by 747 · cited 1×
“Genetic barrier defects decrease the expression of epidermal differentiation-related molecules, such as loricrin and involucrin and tight junction proteins claudin-1 and claudin-23, which are inversely correlated with Th2 biomarkers [20].”
BackgroundThe burden of atopic dermatitis: summary of a report for the National Eczema Association.
Drucker, A. M., Wang, A. R., Li, W.-Q., Sevetson, E., Block, J. K., & Qureshi, A. A. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.07.012 · Cited by 720 · cited 1×
“Due to its increasing incidence, AD is now a huge economic burden for families and society [2].”
BackgroundWollenberg, A., Barbarot, S., Bieber, T., Christen‐Zaech, S., Deleuran, M., Fink‐Wagner, A., Gieler, U., Girolomoni, G., Lau, S., Muraro, A., et al. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14888 · Cited by 684
Noda, S., Suárez-Fariñas, M., Ungar, B., Kim, S. J., de Guzman Strong, C., Xu, H., Peng, X., Estrada, Y. D., Nakajima, S., Honda, T., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.08.015 · Cited by 657 · cited 1×
“The Asian AD phenotype presented with a blended phenotype between that of European American AD and those with psoriasis, of which the skin biopsies exhibited higher Th17 activation and a strong Th2 component [42].”
BackgroundPaller, A. S., Tom, W. L., Lebwohl, M. G., Blumenthal, R. L., Boguniewicz, M., Call, R. S., Eichenfield, L. F., Forsha, D. W., Rees, W. C., Simpson, E. L., et al. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.05.046 · Cited by 577 · cited 1×
“Moreover, it is worth noting that this finding was only slightly higher than that in the vehicle group (18–25%) [83].”
ResultSimpson, E. L., Sinclair, R., Forman, S., Wollenberg, A., Aschoff, R., Cork, M., Bieber, T., Thyssen, J. P., Yosipovitch, G., Flohr, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30732-7 · Cited by 522
Wollenberg, A., Christen‐Zäch, S., Taieb, A., Paul, C., Thyssen, J. P., de Bruin‐Weller, M., Vestergaard, C., Seneschal, J., Werfel, T., Cork, M. J., et al. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16892 · Cited by 493
de Bruin-Weller, M., Thaçi, D., Smith, C. H., Reich, K., Cork, M. J., Radin, A., Zhang, Q., Akinlade, B., Gadkari, A., Eckert, L., et al. (2018) · British Journal of Dermatology · doi:10.1111/bjd.16156 · Cited by 479 · cited 1×
“It is noteworthy that response rates were largely similar in a randomized trial of patients with a history of inadequate responses to or intolerance to cyclosporine [96].”
BackgroundIgE, Mast Cells, and Eosinophils in Atopic Dermatitis
Liu, F.-T., Goodarzi, H., & Chen, H.-Y. (2011) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-011-8252-4 · Cited by 470 · cited 1×
“As an indicator of “atopy,” it is still controversial whether IgE has a pathogenic effect in AD [125].”
BackgroundTopical tofacitinib for atopic dermatitis: a phase II a randomized trial
Bissonnette, R., Papp, K. A., Poulin, Y., Gooderham, M., Raman, M., Mallbris, L., Wang, C., Purohit, V., Mamolo, C., Papacharalambous, J., et al. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14871 · Cited by 420
Song, H., Yoo, Y., Hwang, J., Na, Y.-C., & Kim, H. S. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.08.021 · Cited by 416 · cited 1×
“Furthermore, the feedback interactions between dysbiosis at the Faecalibacterium prausnitzii subspecieslevel in the human gut microbiome and dysregulation of gut epithelial inflammation may underlie AD [29].”
BackgroundSilverberg, J. I., Simpson, E. L., Thyssen, J. P., Gooderham, M., Chan, G., Feeney, C., Biswas, P., Valdez, H., DiBonaventura, M., Nduaka, C., et al. (2020) · JAMA Dermatology · doi:10.1001/jamadermatol.2020.1406 · Cited by 404 · cited 2×
“Abrocitinib (A Selective JAK1 Inhibitor) Two phase III double-blind, randomized, placebo-controlled monotherapy trials have been published and the results of these trials were similar [132, 133].”
BackgroundSimpson, E. L., Lacour, J. ‐., Spelman, L., Galimberti, R., Eichenfield, L. F., Bissonnette, R., King, B. A., Thyssen, J. P., Silverberg, J. I., Bieber, T., et al. (2020) · British Journal of Dermatology · doi:10.1111/bjd.18898 · Cited by 396 · cited 1×
“No serious adverse events such as cardiovascular events, venous thromboembolism, gastrointestinal perforation, or death were observed with any of the baricitinib doses [130].”
BackgroundChng, K. R., Tay, A. S. L., Li, C., Ng, A. H. Q., Wang, J., Suri, B. K., Matta, S. A., McGovern, N., Janela, B., Wong, X. F. C. C., et al. (2016) · Nature Microbiology · doi:10.1038/nmicrobiol.2016.106 · Cited by 388 · cited 1×
“However, a recent study found that a differential reduction in microbial diversity in the gut did not correlate with disease severity, while microbes on the skin and oral cavity were affected [30].”
BackgroundGuttman-Yassky, E., Thaçi, D., Pangan, A. L., Hong, H. C.-H., Papp, K. A., Reich, K., Beck, L. A., Mohamed, M.-E. F., Othman, A. A., Anderson, J. K., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.11.025 · Cited by 369 · cited 1×
“The FDA has granted upadacitinib a “breakthrough therapy designation” for systemic therapy of adults with moderateto-severe AD [129].”
BackgroundTrial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus
Kabashima, K., Matsumura, T., Komazaki, H., & Kawashima, M. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917006 · Cited by 361
Mediators of Chronic Pruritus in Atopic Dermatitis: Getting the Itch Out?
Mollanazar, N. K., Smith, P. K., & Yosipovitch, G. (2016) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-015-8488-5 · Cited by 353 · cited 1×
“1 3 which constituted feed-forward loops [46].”
The effect of environmental humidity and temperature on skin barrier function and dermatitis
Engebretsen, K. A., Johansen, J. D., Kezic, S., Linneberg, A., & Thyssen, J. P. (2016) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.13301 · Cited by 349 · cited 1×
“Furthermore, lower mean temperatures, more indoor heating, lower relative humidity, and lower UV index increased the prevalence of AD [60].”
BackgroundKennedy, E. A., Connolly, J., Hourihane, J. O., Fallon, P. G., McLean, W. H. I., Murray, D., Jo, J.-H., Segre, J. A., Kong, H. H., & Irvine, A. D. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.07.029 · Cited by 348 · cited 1×
“Colonization of the antecubital fossa with commensal staphylococci at month 2 was associated with a decreased incidence of AD at 1 year [28].”
BackgroundGuttman-Yassky, E., Brunner, P. M., Neumann, A. U., Khattri, S., Pavel, A. B., Malik, K., Singer, G. K., Baum, D., Gilleaudeau, P., Sullivan-Whalen, M., et al. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.01.016 · Cited by 343 · cited 1×
“Patients with moderate AD did not achieve significant efficacy [119].”
BackgroundSimpson, E. L., Parnes, J. R., She, D., Crouch, S., Rees, W., Mo, M., & van der Merwe, R. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.11.059 · Cited by 328 · cited 1×
“However, the results were disappointing [115].”
First-in-human topical microbiome transplantation with Roseomonas mucosa for atopic dermatitis
Myles, I. A., Earland, N. J., Anderson, E. D., Moore, I. N., Kieh, M. D., Williams, K. W., Saleem, A., Fontecilla, N. M., Welch, P. A., Darnell, D. A., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.120608 · Cited by 326 · cited 1×
“aureus burden in 10 adults and 5 pediatric patients enrolled in an open-label phase I/II safety and activity trial [90].”
BackgroundBao, L., Zhang, H., & Chan, L. S. (2013) · JAK-STAT · doi:10.4161/jkst.24137 · Cited by 320 · cited 1×
“1 3 receptors on the cell membrane to activate gene transcription and mediate inflammatory cytokines (IL-4, IL-5, IL-13, IL-31, TSLP) to regulate the inflammatory response [86].”
BackgroundSelf-citationGuttman-Yassky, E., Silverberg, J. I., Nemoto, O., Forman, S. B., Wilke, A., Prescilla, R., de la Peña, A., Nunes, F. P., Janes, J., Gamalo, M., et al. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.01.018 · Cited by 317 · cited 1×
“The efficacy of baricitinib on clinical signs and symptoms was similar to that observed in previous trials with no new safety concerns [131].”
ResultDaily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial
Chalmers, J. R., Haines, R. H., Bradshaw, L. E., Montgomery, A. A., Thomas, K. S., Brown, S. J., Ridd, M. J., Lawton, S., Simpson, E. L., Cork, M. J., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(19)32984-8 · Cited by 317 · cited 1×
“The BEEP randomized controlled trial showed no evidence that daily emollients during the first year of life prevented eczema in high-risk children and there was some evidence to suggest an increased risk of skin infections [72].”
BackgroundNattkemper, L. A., Tey, H. L., Valdes-Rodriguez, R., Lee, H., Mollanazar, N. K., Albornoz, C., Sanders, K. M., & Yosipovitch, G. (2018) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.12.029 · Cited by 310
Viral infections in atopic dermatitis
Wollenberg, A., Wetzel, S., Burgdorf, W. H. C., & Haas, J. (2003) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2003.07.001 · Cited by 300 · cited 1×
“1 3 However, when infection occurs, the use of emollients alone without effective anti-inflammatory treatment will significantly increase the risk of disseminated bacterial and viral infections [68].”
BackgroundAtopic dermatitis: the skin barrier and beyond
Tsakok, T., Woolf, R., Smith, C. H., Weidinger, S., & Flohr, C. (2019) · British Journal of Dermatology · doi:10.1111/bjd.16934 · Cited by 287 · cited 1×
“The notable pro-inflammatory cytokines including thymic stromal lipoprotein (TSLP), IL-25, and IL-33 activated Th 2 cells, which promoted specific cytokine-associated inflammation (IL-4, IL-5, IL-13), eosinophilia, and immunoglobulin E (IgE) production [32].”
BackgroundClimatic Factors Are Associated with Childhood Eczema Prevalence in the United States
Silverberg, J. I., Hanifin, J., & Simpson, E. L. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.19 · Cited by 286
Harper, J. I., Ahmed, I., Barclay, G., Lacour, M., Hoeger, P., Cork, M. J., Finlay, A. Y., Wilson, N. J. E., Graham-Brown, R. A. C., Sowden, J. M., et al. (2000) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2000.03241.x · Cited by 281 · cited 1×
“However, short-course therapy was still adequate for some patients [98].”
BackgroundBacterial and Viral Infections in Atopic Dermatitis: a Comprehensive Review
Ong, P. Y., & Leung, D. Y. M. (2016) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-016-8548-5 · Cited by 281 · cited 3×
“aureus in AD lesions has increased [24].”
BackgroundNomura, T., Sandilands, A., Akiyama, M., Liao, H., Evans, A. T., Sakai, K., Ota, M., Sugiura, H., Yamamoto, K., Sato, H., et al. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.12.646 · Cited by 271
Anti-CD20 (rituximab) treatment improves atopic eczema
Simon, D., Hösli, S., Kostylina, G., Yawalkar, N., & Simon, H.-U. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.11.016 · Cited by 255 · cited 1×
“Rituximab Rituximab, an anti-CD20 antibody which deletes B cells, resulted in a rapid improvement in lesional severity in all patients and a sustained effect over 5 months in five of six patients [122].”
BackgroundEpithelial barrier repair and prevention of allergy
Goleva, E., Berdyshev, E., & Leung, D. Y. M. (2019) · Journal of Clinical Investigation · doi:10.1172/jci124608 · Cited by 251
Chen, Y.-L., Gutowska-Owsiak, D., Hardman, C. S., Westmoreland, M., MacKenzie, T., Cifuentes, L., Waithe, D., Lloyd-Lavery, A., Marquette, A., Londei, M., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aax2945 · Cited by 250 · cited 2×
“ANB020 (Etokimab) and REGN3500 A phase II clinical trial of ANB020 (etokimab), an anti-IL-33 monoclonal antibody, is ongoing (NCT03533751).”
MethodNakagawa, H., Nemoto, O., Igarashi, A., Saeki, H., Kaino, H., & Nagata, T. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.12.015 · Cited by 242 · cited 1×
“8% in the placebo group, respectively [87].”
Skjerven, H. O., Rehbinder, E. M., Vettukattil, R., LeBlanc, M., Granum, B., Haugen, G., Hedlin, G., Landrø, L., Marsland, B. J., Rudi, K., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(19)32983-6 · Cited by 234 · cited 1×
“Studies have demonstrated that early complementary feeding between 12 and 16 weeks of age to prevent infant AD by 12 months of age is not suggested [63].”
BackgroundTreatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream
Kim, B. S., Howell, M. D., Sun, K., Papp, K., Nasir, A., & Kuligowski, M. E. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.08.042 · Cited by 226 · cited 1×
“Common mild or moderate adverse reactions were nasopharyngitis, headache, nausea, neutropenia, and diarrhea [88].”
BackgroundGuttman-Yassky, E., Pavel, A. B., Zhou, L., Estrada, Y. D., Zhang, N., Xu, H., Peng, X., Wen, H.-C., Govas, P., Gudi, G., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.11.053 · Cited by 220 · cited 1×
“1 3 More patients achieved EASI 50 in the GBR 830 treatment group compared with the placebo group [116].”
MethodEfficacy and safety of ustekinumab treatment in adults with moderate‐to‐severe atopic dermatitis
Khattri, S., Brunner, P. M., Garcet, S., Finney, R., Cohen, S. R., Oliva, M., Dutt, R., Fuentes‐Duculan, J., Zheng, X., Li, X., et al. (2017) · Experimental Dermatology · doi:10.1111/exd.13112 · Cited by 214 · cited 1×
“A phase II, placebocontrolled clinical trial of ustekinumab combined with TCS failed to achieve statistically significant improvement [121].”
BackgroundWorm, M., Simpson, E. L., Thaçi, D., Bissonnette, R., Lacour, J.-P., Beissert, S., Kawashima, M., Ferrándiz, C., Smith, C. H., Beck, L. A., et al. (2020) · JAMA Dermatology · doi:10.1001/jamadermatol.2019.3617 · Cited by 214
Bae, J. M., Choi, Y. Y., Park, C. O., Chung, K. Y., & Lee, K. H. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.02.044 · Cited by 201 · cited 1×
“It was suggested that the treatment course should be longer than 3 years [107, 108].”
BackgroundHeil, P. M., Maurer, D., Klein, B., Hultsch, T., & Stingl, G. (2010) · JDDG: Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/j.1610-0387.2010.07497.x · Cited by 197 · cited 1×
“Despite favorable results in some case reports, two randomized, double-blind, placebo-controlled trials of omalizumab in children and adults aged 4 years and older showed that the improvement observed in the SCORAD of patients in the omalizumab treatment group was comparable to that in the placebo group [126, 127].”
ResultBaurecht, H., Hotze, M., Brand, S., Büning, C., Cormican, P., Corvin, A., Ellinghaus, D., Ellinghaus, E., Esparza-Gordillo, J., Fölster-Holst, R., et al. (2015) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2014.12.004 · Cited by 193 · cited 1×
“3, was identified as a major predisposing factor for AD [8].”
BackgroundThe exposome in atopic dermatitis
Stefanovic, N., Flohr, C., & Irvine, A. D. (2020) · Allergy · doi:10.1111/all.13946 · Cited by 181 · cited 1×
“Non-specific allergens include air pollutants such as tobacco smoke or volatile organic compounds in indoor environments and traffic exhaust in outdoor air [59].”
BackgroundHaeck, I. M., Knol, M. J., ten Berge, O., van Velsen, S. G. A., de Bruin-Weller, M. S., & Bruijnzeel-Koomen, C. A. F. M. (2011) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2010.04.027 · Cited by 177 · cited 1×
“Furthermore, clinical improvement with ECMPS was delayed compared to cyclosporine, while remission after withdrawal of EC-MPS lasted longer [102].”
BackgroundNavarro-López, V., Ramírez-Boscá, A., Ramón-Vidal, D., Ruzafa-Costas, B., Genovés-Martínez, S., Chenoll-Cuadros, E., Carrión-Gutiérrez, M., Horga de la Parte, J., Prieto-Merino, D., & Codoñer-Cortés, F. M. (2018) · JAMA Dermatology · doi:10.1001/jamadermatol.2017.3647 · Cited by 176 · cited 16×
“Studies found that 5-year long-term management of mild-to-moderate AD in infants with TCSs or pimecrolimus 1% cream was safe without any effect on the immune system [77].”
BackgroundInfluentialPavel, A. B., Zhou, L., Diaz, A., Ungar, B., Dan, J., He, H., Estrada, Y. D., Xu, H., Fernandes, M., Renert-Yuval, Y., et al. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.10.039 · Cited by 168
Prevalence of Atopic Dermatitis in Chinese Children aged 1–7 ys
Guo, Y., Li, P., Tang, J., Han, X., Zou, X., Xu, G., Xu, Z., Wei, F., Liu, Q., Wang, M., et al. (2016) · Scientific Reports · doi:10.1038/srep29751 · Cited by 166 · cited 1×
“94% among children aged 1–7 years [6].”
Self-citationAtopic dermatitis phenotypes and the need for personalized medicine
Cabanillas, B., Brehler, A.-C., & Novak, N. (2017) · Current Opinion in Allergy & Clinical Immunology · doi:10.1097/aci.0000000000000376 · Cited by 155 · cited 1×
“The individual pathogenesis urged the development of targeted and phenotype-specific therapies for AD [57].”
BackgroundEichenfield, L. F., Call, R. S., Forsha, D. W., Fowler, J., Hebert, A. A., Spellman, M., Stein Gold, L. F., Van Syoc, M., Zane, L. T., & Tschen, E. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.06.010 · Cited by 154 · cited 1×
“The role of crisaborole in the treatment of AD remains to be evaluated, but it may provide another topical nonsteroidal drug for patients with mild-to-moderate AD [84, 85].”
BackgroundIyengar, S. R., Hoyte, E. G., Loza, A., Bonaccorso, S., Chiang, D., Umetsu, D. T., & Nadeau, K. C. (2013) · International Archives of Allergy and Immunology · doi:10.1159/000350486 · Cited by 151
Safety and Efficacy of Pimecrolimus in Atopic Dermatitis: A 5-Year Randomized Trial
Sigurgeirsson, B., Boznanski, A., Todd, G., Vertruyen, A., Schuttelaar, M.-L. A., Zhu, X., Schauer, U., Qaqundah, P., Poulin, Y., Kristjansson, S., et al. (2015) · Pediatrics · doi:10.1542/peds.2014-1990 · Cited by 149
Japanese guidelines for atopic dermatitis 2017
Katayama, I., Aihara, M., Ohya, Y., Saeki, H., Shimojo, N., Shoji, S., Taniguchi, M., & Yamada, H. (2017) · Allergology International · doi:10.1016/j.alit.2016.12.003 · Cited by 149
Danso, M. O., Boiten, W. A., van Drongelen, V., Meijling, K. A. G., Gooris, G. S., Ghalbzouri, A. E., Absalah, S., Vreeken, R. J., Kežić, S., van Smeden, J., et al. (2017) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2017.05.005 · Cited by 149 · cited 1×
“Decreased levels of total ceramides and changes in ceramide composition have been reported on both lesional and non-lesional skin of patients with AD [23].”
BackgroundZhou, L., Leonard, A., Pavel, A. B., Malik, K., Raja, A., Glickman, J., Estrada, Y. D., Peng, X., del Duca, E., Sanz-Cabanillas, J., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.01.015 · Cited by 146 · cited 1×
“Moreover, serum IgE levels and eosinophil counts negatively correlated with age in patients with AD [40].”
BackgroundBatista, D. I. S., Perez, L., Orfali, R. L., Zaniboni, M. C., Samorano, L. P., Pereira, N. V., Sotto, M. N., Ishizaki, A. S., Oliveira, L. M. D. S., Sato, M. N., et al. (2014) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.12753 · Cited by 144 · cited 1×
“In chronic AD, skin recruitment of Th1 cells appeared to result in a mixed Th1, Th2 and Th22 cell infiltration [34].”
BackgroundAscott, A., Mulick, A., Yu, A. M., Prieto-Merino, D., Schmidt, M., Abuabara, K., Smeeth, L., Roberts, A., & Langan, S. M. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.11.030 · Cited by 144 · cited 1×
“AD is also associated with mental disorders as well as cardiovascular diseases [1].”
BackgroundWerfel, T., Layton, G., Yeadon, M., Whitlock, L., Osterloh, I., Jimenez, P., Liu, W., Lynch, V., Asher, A., Tsianakas, A., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.07.047 · Cited by 139 · cited 1×
“It is noteworthy that a 3-point reduction (scale, 1–10) in pruritus occurred with oral ZPL-3893787 versus a similar reduction with placebo [111].”
Myles, I. A., Castillo, C. R., Barbian, K. D., Kanakabandi, K., Virtaneva, K., Fitzmeyer, E., Paneru, M., Otaizo-Carrasquero, F., Myers, T. G., Markowitz, T. E., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz8631 · Cited by 139 · cited 1×
“mucosa persisted for up to 8 months after cessation of treatment [91].”
BackgroundEfficacy of omalizumab in patients with atopic dermatitis: A systematic review and meta-analysis
Wang, H.-H., Li, Y., & Huang, Y. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.05.038 · Cited by 138 · cited 1×
“A meta-analysis of 103 patients from two RCTs and 13 case reports showed that omalizumab had no significant effect on AD [128].”
BackgroundMurakami-Satsutani, N., Ito, T., Nakanishi, T., Inagaki, N., Tanaka, A., Vien, P. T. X., Kibata, K., Inaba, M., & Nomura, S. (2014) · Allergology International · doi:10.2332/allergolint.13-oa-0672 · Cited by 135 · cited 1×
“Moreover, TSLP, TSLP receptor, OX40, OX40L, and IL-33 are significantly upregulated in lesional skin [113].”
BackgroundBissonnette, R., Maari, C., Forman, S., Bhatia, N., Lee, M., Fowler, J., Tyring, S., Pariser, D., Sofen, H., Dhawan, S., et al. (2019) · British Journal of Dermatology · doi:10.1111/bjd.17932 · Cited by 130 · cited 1×
“ASN002, Dual JAK‐Spleen Tyrosine Kinase (SYK) Inhibitor A phase Ib proof-of-concept trial with 36 moderate-to-severe AD patients reported 100% of patients assigned to ASN002 40 mg and 83% of patients given 80 mg of ASN002 achieved EASI 50 compared to 22% of patients treated with placebo [134].”
Kempers, S. E., Boguniewicz, M., Carter, E., Jarratt, M., Pariser, D. M., Stewart, D. M., Stiller, M., Tschen, E. H., Chon, K., Wisseh, S., et al. (2004) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2004.01.051 · Cited by 128
du Toit, G., Sayre, P. H., Roberts, G., Lawson, K., Sever, M. L., Bahnson, H. T., Fisher, H. R., Feeney, M., Radulovic, S., Basting, M., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.09.034 · Cited by 122 · cited 1×
“Furthermore, peanut consumption had no preventative effect on the development of asthma and allergic rhinoconjunctivitis [64].”
Backgroundvan Smeden, J., Boiten, W. A., Hankemeier, T., Rissmann, R., Bouwstra, J., & Vreeken, R. (2014) · Biochimica et Biophysica Acta · doi:10.1016/j.bbalip.2013.10.002 · Cited by 121 · cited 1×
“In AD patients, the levels of long-chain ceramides (> 42 carbon atoms) decreased and the level of short-chain ceramides (< 42 carbon atoms) increased compared with healthy control subjects [69].”
BackgroundHypothalamic-Pituitary-Adrenal Function and Glucocorticoid Sensitivity in Atopic Dermatitis
Ellison, J. A., Patel, L., Ray, D. W., David, P. T. J., & Clayton, P. E. (2000) · Pediatrics · doi:10.1542/peds.105.4.794 · Cited by 121 · cited 1×
“Adverse reactions of TCS such as skin atrophy, telangiectasia, hypertrichosis, dyspigmentation, and secondary or aggravated infection should be strictly monitored [76].”
BackgroundAtopic dermatitis in Chinese patients shows TH2/TH17 skewing with psoriasiform features
Chan, T. C., Sanyal, R. D., Pavel, A. B., Glickman, J., Zheng, X., Xu, H., Cho, Y.-T., Tsai, T.-F., Wen, H.-C., Peng, X., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.06.016 · Cited by 114 · cited 1×
“Previous studies have shown that Asian AD has psoriasiform features [120].”
ResultBlood natural killer cell deficiency reveals an immunotherapy strategy for atopic dermatitis
Mack, M. R., Brestoff, J. R., Berrien-Elliott, M. M., Trier, A. M., Yang, T.-L. B., McCullen, M., Collins, P. L., Niu, H., Bodet, N. D., Wagner, J. A., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay1005 · Cited by 111 · cited 1×
“A NK cellboosting interleukin-15 (IL-15) super-agonist could significantly improve AD-like symptoms in mice [37].”
BackgroundClinical Features of Adult/Adolescent Atopic Dermatitis and Chinese Criteria for Atopic Dermatitis
Liu, P., Zhao, Y., Mu, Z.-L., Lu, Q.-J., Zhang, L., Yao, X., Zheng, M., Tang, Y.-W., Lu, X.-X., Xia, X.-J., et al. (2016) · Chinese Medical Journal · doi:10.4103/0366-6999.178960 · Cited by 109
Self-citationGoujon, C., Viguier, M. A., Staumont-Sallé, D., Bernier, C., Guillet, G., Lahfa, M., le Bouëdec, M.-C. F., Cambazard, F., Bottigioli, D., Grande, S., et al. (2017) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2017.07.007 · Cited by 109
Topical hypochlorite ameliorates NF-κB–mediated skin diseases in mice
Leung, T. H., Zhang, L. F., Wang, J., Ning, S., Knox, S. J., & Kim, S. K. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70895 · Cited by 107
The prevalence and persistence of atopic dermatitis in urban United States children
McKenzie, C., & Silverberg, J. I. (2019) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2019.05.014 · Cited by 105 · cited 1×
“5% in children aged 5, 9, and 15 years, respectively [4].”
BackgroundAn assessment of the use of antihistamines in the management of atopic dermatitis
He, A., Feldman, S. R., & Fleischer, A. B. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.12.077 · Cited by 96 · cited 1×
“1 3 antihistamines on sleep quality (delayed and reduced rapideye-movement sleep) and cognitive ability, the long-term use of first-generation antihistamines is not recommended, especially in children [94].”
BackgroundSystematic Review of Diagnostic Criteria Used in Atopic Dermatitis Randomized Controlled Trials
Vakharia, P. P., Chopra, R., & Silverberg, J. I. (2017) · American Journal of Clinical Dermatology · doi:10.1007/s40257-017-0299-4 · Cited by 94 · cited 1×
“The Hanifin and Rajka criteria (H&R criteria) and UK diagnostic criteria (UK criteria) are the most recognized and used criteria for AD globally [48].”
BackgroundLee, Y. W., Won, C. H., Jung, K.-M., Nam, H. ‐., Choi, G., Park, Y. ‐., Park, M., & Kim, B. J. (2019) · British Journal of Dermatology · doi:10.1111/bjd.17455 · Cited by 93 · cited 1×
“The EASI 75/90, sleep disturbance score, and pruritus VAS exhibited a trend towards improvement [135].”
BackgroundPhototherapy for atopic dermatitis
Rodenbeck, D. L., Silverberg, J. I., & Silverberg, N. B. (2016) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2016.05.011 · Cited by 92
Anti-CD20 (rituximab) treatment for atopic eczema
Šedivá, A., Kayserová, J., Vernerová, E., Poloučková, A., Čapková, Š., Špíšek, R., & Bartůňková, J. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.03.007 · Cited by 89 · cited 1×
“However, a report on two cases with severe AD receiving rituximab did not confirm the above findings [123].”
ResultNonlesional atopic dermatitis skin shares similar T‐cell clones with lesional tissues
Brunner, P. M., Emerson, R. O., Tipton, C., Garcet, S., Khattri, S., Coats, I., Krueger, J. G., & Guttman‐Yassky, E. (2017) · Allergy · doi:10.1111/all.13223 · Cited by 88 · cited 16×
“Studies found that 5-year long-term management of mild-to-moderate AD in infants with TCSs or pimecrolimus 1% cream was safe without any effect on the immune system [77].”
BackgroundInfluentialYang, H., Wang, J., Zhang, X., Zhang, Y., Qin, Z.-L., Wang, H., & Luo, X.-Y. (2019) · JAMA Dermatology · doi:10.1001/jamadermatol.2019.0008 · Cited by 85 · cited 1×
“Blocking PDE-4 could reduce the expression of inflammatory mediators and relieve the symptoms of AD [82].”
BackgroundBroeders, J. A., Ahmed Ali, U., & Fischer, G. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.02.1228 · Cited by 84 · cited 2×
“Studies found that 5-year long-term management of mild-to-moderate AD in infants with TCSs or pimecrolimus 1% cream was safe without any effect on the immune system [77].”
BackgroundTreatment of Eczema: Corticosteroids and Beyond
Chong, M., & Fonacier, L. S. (2015) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-015-8486-7 · Cited by 83 · cited 1×
“Different dosage forms and intensities of corticosteroids were selected to effectively control inflammation according to the patient’s age, skin lesion, location, and disease severity [73].”
BackgroundMutations in the filaggrin gene in Han Chinese patients with atopic dermatitis
Zhang, H., Guo, Y., Wang, W., Shi, M., Chen, X., & Yao, Z. (2011) · Allergy · doi:10.1111/j.1398-9995.2010.02493.x · Cited by 81
Self-citationGuo, Y. X., Zhang, H., Liu, Q., Wei, F., Tang, J., Li, P., Han, X., Zou, X., Xu, G., Xu, Z., et al. (2019) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15618 · Cited by 77
Self-citationMcClanahan, D. R., Wong, A., Kežić, S., Samrao, A., Hajar, T., Hill, E. E., & Simpson, E. L. (2019) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15786 · Cited by 76
Peled, A., Sarig, O., Sun, G., Samuelov, L., Ma, C. A., Zhang, Y., Dimaggio, T., Nelson, C. G., Stone, K. D., Freeman, A. F., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.09.002 · Cited by 75 · cited 1×
“LoF mutations in caspase recruitment domain-containing protein 14 (CARD14) were associated with a severe variant of AD [19], which impaired epidermal secretion of antimicrobial peptides and hCCL20.”
BackgroundWen, H.-C., Czarnowicki, T., Noda, S., Malik, K., Pavel, A. B., Nakajima, S., Honda, T., Shin, J. U., Lee, H., Chou, M., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.02.047 · Cited by 73 · cited 1×
“Furthermore, compared with European American AD, Asian AD serum was characterized by significant Th2 and Th22 inflammation which correlated with the non-lesional skin profile [43].”
Nicol, N. H., Boguniewicz, M., Strand, M. J., & Klinnert, M. D. (2014) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2014.04.009 · Cited by 69 · cited 1×
“Short-term (usually 3 days, no more than 14 days) wet wrap therapy is recommended for acute generalized severe or refractory skin lesions, which can quickly and effectively control symptoms, and this treatment is especially suitable for children unsuitable for systematic therapy [75].”
BackgroundThe panoply of αβT cells in the skin
Nomura, T., Kabashima, K., & Miyachi, Y. (2014) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2014.07.010 · Cited by 68 · cited 1×
“responses with antigen re-exposure [35].”
Orciani, M., Campanati, A., Caffarini, M., Ganzetti, G., Consales, V., Lucarini, G., Offidani, A., & Primio, R. D. (2016) · British Journal of Dermatology · doi:10.1111/bjd.15078 · Cited by 68
Langan, S., Irvine, A. D., & Stephan, W. (2020) · The Lancet · Cited by 68
Phosphodiesterase 4 inhibitors as novel anti-inflammatory agents
Doherty, A. M. (1999) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(99)80068-4 · Cited by 67 · cited 2×
“PDE-4 promotes the synthesis of inflammatory cytokines (IL-4, IL-13, IL-22, etc.) and chemokines by degrading intracellular cyclic adenosine monophosphate (cAMP) and reducing the production of anti-inflammatory factors (IL-10) [81].”
BackgroundShi, B., Leung, D. Y. M., Taylor, P. A., & Li, H. (2018) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.01.022 · Cited by 65 · cited 1×
“aureus) colonized the skin in 60–100% of AD patients compared with 5–30% of healthy controls [25].”
BackgroundSelf-citationImpact of Immunoglobulin Therapy in Pediatric Disease: a Review of Immune Mechanisms
Wong, P. H., & White, K. (2015) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-015-8499-2 · Cited by 64 · cited 1×
“IVIG treatment might be considered a last resort for severe refractory AD in children [105].”
BackgroundAssociation of Filaggrin Loss-of-Function Variants With Race in Children With Atopic Dermatitis
Margolis, D. J., Mitra, N., Wubbenhorst, B. S., D'Andrea, K. P., Kraya, A., Hoffstad, O., Shah, S. A., & Nathanson, K. L. (2019) · JAMA Dermatology · doi:10.1001/jamadermatol.2019.1946 · Cited by 61 · cited 1×
“3% in African American individuals [10].”
Distinct clinical features and serum cytokine pattern of elderly atopic dermatitis in China
Wang, S., Zhu, R., Gu, C., Zou, Y., Yin, H., Xu, J., & Li, W. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16346 · Cited by 59 · cited 1×
“However, another study showed that serum levels of IL-4, TARC, IL-17A, IL-6, IL-22, IL-33, and TSLP were significantly higher in elderly AD patients (> 60 years) than in healthy controls, indicating a mixed Th2/Th17/Th22 inflammation [41].”
BackgroundBlunder, S., Rühl, R., Moosbrugger-Martinz, V., Krimmel, C., Geisler, A., Zhu, H., Crumrine, D., Elias, P. M., Gruber, R., Schmuth, M., et al. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.09.034 · Cited by 58 · cited 1×
“radatory proteases and decreased the activity of the lipid synthesis enzymes [22].”
BackgroundGerbens, L. A. A., Hamann, S. A. S., Brouwer, M. W. D., Roekevisch, E., Leeflang, M., & Spuls, P. I. (2017) · British Journal of Dermatology · doi:10.1111/bjd.16240 · Cited by 55 · cited 1×
“A relatively small study showed that methotrexate and azathioprine seemed to be effective and safe as maintenance treatments for moderate-to-severe AD up to 5 years [101].”
BackgroundOldhoff, J. M., Darsow, U., Werfel, T., Bihari, I. C., Katzer, K., Laifaoui, J., Plötz, S., Kapp, A., Knol, E. F., Bruijnzeel-Koomen, C. A. F. M., et al. (2006) · International Archives of Allergy and Immunology · doi:10.1159/000095299 · Cited by 54 · cited 1×
“Previous studies demonstrated that a rapid depletion of eosinophils was observed in peripheral blood, but the improvement in lesional severity was moderate and the atopy patch test reactions were not relieved [124].”
ResultMycophenolate mofetil and atopic dermatitis: systematic review and meta-analysis
Phan, K. H., & Smith, S. D. (2019) · Journal of Dermatological Treatment · doi:10.1080/09546634.2019.1642996 · Cited by 53 · cited 1×
“This agent could be considered an alternative treatment option in individual cases with some evidence of safety and efficacy [103].”
BackgroundLooman, K. I. M., van Meel, E. R., Großerichter-Wagener, C., Vissers, F. J. M., Klingenberg, J. H., de Jong, N. W., de Jongste, J. C., Pasmans, S. G. M. A., Duijts, L., van Zelm, M. C., et al. (2019) · Allergy · doi:10.1111/all.14010 · Cited by 53 · cited 1×
“A recent study found that children with AD had higher Th2, Treg, Treg-memory, and CD27+ IgA+ memory B-cell numbers compared to children without atopic disease [39].”
BackgroundFilaggrin mutations in relation to skin barrier and atopic dermatitis in early infancy*
Hoyer, A., Rehbinder, E. M., Färdig, M., Asad, S., Carlsen, K., Endre, K. M. A., Granum, B. B., Haugen, G. N., Hedlin, G., Jonassen, C. M., et al. (2021) · British Journal of Dermatology · doi:10.1111/bjd.20831 · Cited by 52
IL-22 derived from γδ T cells restricts Staphylococcus aureus infection of mechanically injured skin
Malhotra, N., Yoon, J., Leyva-Castillo, J. M., Galand, C., Archer, N., Miller, L. S., & Geha, R. S. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.07.001 · Cited by 50 · cited 1×
“Th22 Pathway as a Therapy Target IL-22 is significantly elevated in AD lesional skin and is correlated with disease severity [118].”
BackgroundAkan, A., Dibek-Mısırlıoğlu, E., Civelek, E., Vezir, E., & Kocabaş, C. N. (2019) · Allergologia et Immunopathologia · doi:10.1016/j.aller.2019.07.008 · Cited by 50 · cited 1×
“The H&R criteria were superior to the UK criteria for sensitivity and negative predictive value, but inferior for specificity and positive predictive value [49].”
BackgroundCao, L., Wang, L., Yang, L., Tao, S., Xia, R., & Fan, W. (2015) · Journal of Dermatological Treatment · doi:10.3109/09546634.2015.1027168 · Cited by 49 · cited 1×
“A meta-analysis, which included 1955 eligible patients, demonstrated that the administration of probiotics during pregnancy and in early life could be an effective tool in the primary prevention of AD during a long-term follow-up period [137].”
MethodKaffenberger, B. H., Mathis, J. G., & Zirwas, M. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.04.045 · Cited by 49 · cited 1×
“Antifungal Malassezia may be involved in the pathogenesis of a “head and neck” AD subtype or anti-Malassezia IgE positive patients, and topical or systemic azole antifungal drugs may be used [110].”
BackgroundShi, V. Y., Foolad, N., Ornelas, J. N., Hassoun, L. A., Monico, G., Takeda, N., Saric, S., Prakash, N., Eichenfield, L. F., & Sivamani, R. K. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14483 · Cited by 48 · cited 1×
“A bleach bath was tolerated, safe, and had no negative effect on stratum corneum hydration, trans-epidermal water loss (TEWL), or pH value [67].”
BackgroundMucha, S., Baurecht, H., Novak, N., Rodríguez, E., Bej, S., Mayr, G., Emmert, H., Stölzl, D., Gerdes, S., Jung, E. S., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.10.030 · Cited by 48 · cited 1×
“Novel mutations in Docking protein 2 (DOK2) and CD200 receptor 1 (CD200R1) may influence the regulation of ERK signaling downstream of Toll-like receptor 4 and maturation of NK cells [18].”
BackgroundMoriwaki, M., Iwamoto, K., Niitsu, Y., Matsushima, A., Yanase, Y., Hisatsune, J., Sugai, M., & Hide, M. (2018) · Allergy · doi:10.1111/all.13622 · Cited by 46 · cited 2×
“A recent study demonstrated that S. aureus from patients with AD accumulated in the lysosomes of keratinocytes by means of bacterial cell wall proteins and mediated IL-1α via TLR9 [27].”
BackgroundLuukkonen, T., Kiiski, V., Ahola, M., Mandelin, J. M., Virtanen, H. M., Pöyhönen, M., Kivirikko, S., Surakka, I. L., Reitamo, S., Palotie, A. V., et al. (2016) · Acta Dermato Venereologica · doi:10.2340/00015555-2578 · Cited by 42 · cited 1×
“FLG mutations were found to be significantly associated with early-onset AD (< 2 years) and asthma [9].”
BackgroundFilaggrin Mutation in Korean Patients with Atopic Dermatitis
On, H. R., Lee, S. E., Kim, S., Hong, W. J., Kim, H. J., Nomura, T., Suzuki, S., Shimizu, H., & Kim, S. (2017) · Yonsei Medical Journal · doi:10.3349/ymj.2017.58.2.395 · Cited by 42
Development and validation of new diagnostic criteria for atopic dermatitis in children of China
Cheng, R., Zhang, H., Zong, W., Tang, J., Han, X., Zhang, L., Zhang, X., Gu, H., Shu, Y., Peng, G., et al. (2019) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15979 · Cited by 42
Self-citationMutations analysis in filaggrin gene in northern China patients with atopic dermatitis
Li, M., Liu, Q., Liu, J., Cheng, R., Zhang, H., Xue, H., Bao, Y., & Yao, Z. (2013) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2011.04435.x · Cited by 38
Self-citationAhmed, A. I., Šolman, L., & Williams, H. C. (2017) · British Journal of Dermatology · doi:10.1111/bjd.16046 · Cited by 37 · cited 1×
“The role of crisaborole in the treatment of AD remains to be evaluated, but it may provide another topical nonsteroidal drug for patients with mild-to-moderate AD [84, 85].”
BackgroundAndersen, L., Nyeland, M. E., & Nyberg, F. (2019) · British Journal of Dermatology · doi:10.1111/bjd.18451 · Cited by 37
Hua, T., Yousaf, M., Gwillim, E. C., Yew, Y. W., Lee, B., Hua, K., Erickson, T. R., Cheng, B. T., & Silverberg, J. I. (2020) · Archives of Dermatological Research · doi:10.1007/s00403-020-02164-0 · Cited by 37
Ishida, K., Takahashi, A., Bito, K., Draelos, Z. D., & Imokawa, G. (2020) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.01.014 · Cited by 35 · cited 1×
“Four weeks of treatment with designed synthetic pseudo-ceramide lotion in thirty-eight AD patients significantly reduced skin symptoms, accompanied by significant decreases in TEWL and a switch of stratum corneum ceramide profiles from an AD to a healthy skin phenotype [70].”
BackgroundMöbus, L., Rodríguez, E., Harder, I., Schwarz, A., Wehkamp, U., Stölzl, D., Sander, N., Gerdes, S., Litman, T., Kleinheinz, A., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.11.022 · Cited by 35 · cited 1×
“However, another study found that the NK-cell transcriptomic signature remained upregulated even after dupilumab and cyclosporine treatment with a dysbalance of decrease in activated NK cells and an increase in resting NK cells in both lesional and nonlesional skin [38].”
Background‘High dose’ vs. ‘medium dose’ UVA1 phototherapy in italian patients with severe atopic dermatitis
Pacifico, A., Iacovelli, P., Damiani, G. B., Ferraro, C., Cazzaniga, S., Conic, R. R. Z., Leone, G., & Morrone, A. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15362 · Cited by 34 · cited 1×
“Studies showed that highdose UVA1 phototherapy was more effective than medium dose in the treatment of adult patients with severe generalized AD, especially those with darker skin types [93].”
BackgroundMajewski, S., Bhattacharya, T., Asztalos, M., Bohaty, B. R., Durham, K. C., West, D. P., Hebert, A. A., & Paller, A. S. (2019) · Pediatric Dermatology · doi:10.1111/pde.13842 · Cited by 34 · cited 1×
“005% bleaching bath powder) can be added to the bath to inhibit bacterial activity, which is helpful in alleviating AD [66].”
BackgroundEMSY expression affects multiple components of the skin barrier with relevance to atopic dermatitis
Elias, M. S., Wright, S. C., Reményi, J., Abbott, J., Bray, S. E., Cole, C., Edwards, S., Gierliński, M., Glok, M., McGrath, J. A., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.05.024 · Cited by 29 · cited 1×
“5, reduced longchain ceramides and decreased cell–cell adhesion structures [17].”
BackgroundScratching damages tight junctions through the Akt–claudin 1 axis in atopic dermatitis
Hu, X., Tang, Y., Ju, Y., Zhang, X. Y., Yan, J.-Y., Wang, C., Yang, Y., Zhu, C., Tang, Z., Zhou, Y., et al. (2020) · Clinical and Experimental Dermatology · doi:10.1111/ced.14380 · Cited by 29 · cited 1×
“Skin barrier dysfunction enhanced transcutaneous microbial and allergen penetration, and reduced inflammatory thresholds to haptens and irritants [31].”
BackgroundDiagnosing atopic dermatitis in infancy using established diagnostic criteria: a cohort study
Endre, K. M. A., Landrø, L., LeBlanc, M., Gjersvik, P. J., Carlsen, K. C. L., Haugen, G. N., Hedlin, G., Jonassen, C. M., Nordlund, B., Rudi, K., et al. (2022) · British Journal of Dermatology · doi:10.1111/bjd.19831 · Cited by 29 · cited 1×
“A cohort study including 1834 infants showed that UK criteria and H&R criteria used in combination and at multiple time points might be useful in clinical research, but might have limited value in most other clinical settings [50].”
BackgroundSelective role of neurokinin B in IL-31–induced itch response in mice
Sakata, D., Uruno, T., Matsubara, K., Andoh, T., Yamamura, K., Magoshi, Y., Kunimura, K., Kamikaseda, Y., Furue, M., & Fukui, Y. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.06.031 · Cited by 25 · cited 1×
“Th2 Pathway as a Therapy Target IL-31 is known as the itch cytokine and is an important factor in the resistant itchscratch cycle of AD [112].”
BackgroundZhong, H., Deng, X., Song, Z., Darsow, U. G., Chen, W., Chen, S., Luo, N., & Hao, F. (2014) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.12813 · Cited by 24 · cited 1×
“It was suggested that the treatment course should be longer than 3 years [107, 108].”
BackgroundWang, I., & Lin, T.-J. (2014) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2014.10.019 · Cited by 22 · cited 1×
“The FLG variants R501X and 2282del4 were found in approximately 10% of Northern Europeans [15], while FLG variants of P478S and 3321delA were found mainly in Asian AD populations, and rarely in European populations [16].”
BackgroundBasophils add fuel to the flame of eczema itch
Mali, S. S., & Bautista, D. M. (2021) · Cell · doi:10.1016/j.cell.2020.12.035 · Cited by 22 · cited 1×
“Unrecognized basophil-leukotriene (LT) axis and LTC4-CysLTR2 neuroimmune axis emerged as critical for it [47].”
BackgroundKim, J. E., Shin, J. M., Ko, J. Y., & Ro, Y. S. (2016) · Dermatologic Therapy · doi:10.1111/dth.12333 · Cited by 19 · cited 1×
“Although cyclosporine monotherapy is effective against AD, topical agents should be used concomitantly to achieve a higher success rate during the 3 months after discontinuation of cyclosporine [99].”
BackgroundEffects of lidocaine on regulatory T cells in atopic dermatitis
Li, H., Li, C., Zhang, H., Zhang, L., Cheng, R., Li, M., Guo, Y., Zhang, Z., Lu, Z., Zhuang, Y., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.07.039 · Cited by 17 · cited 6×
“* Yifeng Guo guoyifeng@xinhuamed.com.cn * Zhirong Yao yaozhirong@xinhuamed.com.cn 1 Department of Dermatology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China 2 Institute of Dermatology, Shanghai Jiaotong University School of Medicine, Shanghai, China TEWL Trans-epidermal water loss T…”
BackgroundInfluentialSelf-citationFamily management of childhood atopic dermatitis
Son, H. K., Kim, D. H., Lee, H., Kim, H., Chung, K., & Kim, H. (2018) · Journal of Advanced Nursing · doi:10.1111/jan.13551 · Cited by 16 · cited 1×
“Family management of refractory childhood AD and management in the school setting were suggested to adopt effective avoidance strategies, monitor regular medication, and reduce recurrence [55, 56].”
Backgroundカスパーゼ動員ドメイン含有蛋白質14(CARD14)における機能喪失変異はアトピー性皮膚炎の重症変異体と関連する【JST・京大機械翻訳】
Alon, P., Ofer, S., Guang-ping, S., Samuelov, L., Ma, A. I., Zhang, Y., DiMaggio, T., Celeste, G. N., Kelly, D. S., Alexandra, F. F., et al. (2019) · Journal of Allergy and Clinical Immunology · Cited by 14
Current status in diagnosis of atopic dermatitis in China
Cheng, R., Guo, Y. X., Huang, L., Hao, F., Gao, X., Bieber, T. R. M., & Yao, Z. (2017) · Allergy · doi:10.1111/all.13149 · Cited by 13
Self-citationTopical Calcineurin Inhibitors, Topical Glucocorticoids and Cancer in Children: A Nationwide Study
Deleuran, M. S., Vestergaard, C., Vølund, A., & Thestrup‐Pedersen, K. (2014) · Acta Dermato Venereologica · doi:10.2340/00015555-2392 · Cited by 12 · cited 10×
“Clinical observation did not indicate an increased risk of the occurrence of lymphoma or other types of malignancies or photocarcinogenicity for TCI [78, 80].”
BackgroundInfluentialBreslin, M. E., Lin, J. H., Roberts, R. L., Lim, K. J., & Stiehm, E. R. (2016) · Allergy & Rhinology · doi:10.2500/ar.2016.7.0164 · Cited by 12
Atopic Dermatitis: Management in the School Setting
Schoessler, S. Z. (2019) · NASN School Nurse · doi:10.1177/1942602x19856873 · Cited by 2 · cited 1×
“Family management of refractory childhood AD and management in the school setting were suggested to adopt effective avoidance strategies, monitor regular medication, and reduce recurrence [55, 56].”
Background
Cited by
Recent advances in understanding the role of IL-4 signaling
Keegan, A. D., Leonard, W. J., & Zhu, J. (2021) · Faculty Reviews · doi:10.12703/r/10-71 · Cited by 154
An Overview of PDE4 Inhibitors in Clinical Trials: 2010 to Early 2022
Crocetti, L., Floresta, G., Cilibrizzi, A., & Giovannoni, M. P. (2022) · Molecules · doi:10.3390/molecules27154964 · Cited by 129
Huang, F., Lu, X., Kuai, L., Ru, Y., Jiang, J., Song, J., Chen, S., Mao, L., Li, Y., Li, B., et al. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.3c11059 · Cited by 123
Tsiogka, A., Kyriazopoulou, M., Kontochristopoulos, G., Nicolaidou, E., Stratigos, A., Rigopoulos, D., & Gregoriou, S. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11154431 · Cited by 103
“Current knowledge suggests that robust activation of the T-helper (Th)-2 [interleukin (IL)-4, IL-5, IL-13, IL-31] and Th22 (IL-22) immune responses in both skin and serum play a pivotal role in the immunopathogenesis of AD especially at the acute stage, followed by a variable degree of Th1[interferon-γ (IFN-γ), tumor…”
BackgroundLimosilactobacillus reuteri in immunomodulation: molecular mechanisms and potential applications
Luo, Z., Chen, A., Xie, A., Liu, X., Jiang, S., & Yu, R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1228754 · Cited by 94
Metadata
- Authors
- Li, H., Zhang, Z., Zhang, H., Guo, Y., & Yao, Z.
- Affiliations
- Shanghai Jiao Tong University (CN)
- Corresponding author
- Guo, Yifeng
- Yao, Zhirong
- Venue
- Clinical Reviews in Allergy & Immunology
- Published
- 2021-08-02
- Volume
- 61
- Issue
- 3
- Pages
- 324-338
- ISSN
- 1080-0549 (ISSN-L)
- 1559-0267
- OpenAlex
- W3192687721
- Semantic Scholar
- 2455c8867c90afc6e1d277b48077606f29743af5
- Cited by
- 277
- References
- 141
- Citations by year
- 2026: 43 · 2025: 77 · 2024: 84 · 2023: 46 · 2022: 25 · 2021: 2
- FWCI
- 7.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Clinical Reviews in Allergy & Immunology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Dermatology › Contact Dermatitis and Allergies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Keywords
- atopic dermatitis, pathogenesis, skin barrier dysfunction, skin microbiome, immune dysregulation, type 2 inflammation, pruritus, NK cell deficiency, gut microbiota, Roseomonas mucosa, microbiota transplantation, phosphodiesterase-4 inhibitors, JAK inhibitors, IL-23/Th17 pathway, topical corticosteroids, antipruritic therapy, probiotics
- MeSH terms
- Dermatitis, Atopic, Humans
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.